
Research Studies
Principal Investigator: Ali Ahmed, M.D
- Physical fitness as an objective biomarker for AD/ADRD risk modification.
- Magnesium supplement and vascular health: Machine learning from the longitundinal medical record.
- MWAS+ – A Novel Drug Repurposing Strategy for ADRD Prevention.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Joao Ascensao, M.D
- Identification of Targetable Prostate Cancer Alterations Through Tumor DNA Screening.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Omar Aman, M.D
1. 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Anita Aggarwal, M.D
1. ANT007: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER).
2. A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnoli).
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Bidhan Bandyopadhyay, M.D
1. Calcium transport in kidney proximal tubule and calcium phosphate stone formation.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Benator, M.D
1. City-wide DC cohort of HIV infected persons in care in the District of Columbia.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Marc Blackman, M.D
1. Participant and Clinical (PCI) and Intergrating special Populations (ISP) (HLT/HUB).
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Julie Chapman, M.D
1. Cerebrovascular reactivity and oxygen metabolism as markers of neurodegeneration after traumatic brain injury.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Gibert Weintrob, M.D
1. Advancing High Quality COPD care for people with immune dysfunction by implementing evidence based management through proactive E- Consults (ACHIEVE).
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Katharine Harper, M.D
1. A Randomized Controlled Trial of Alternating Irrigation of Vancomycin HCl and Tobramycin Sulfate in Patients Undergoing Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection of Hip or Knee.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Amy Weintrob, M.D
1. FLU 003 Plus (Zrespiratory Virus Hospitalization Study, INSIGHT Protocol No. 003) and FLU 004 (Genomics).
2. COVID 19 Study_ Observational Study (INSIGHT 011).
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Gail Kerr, M.D
1. Identifying Novel Biomarkers of Disease Progression in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Mary Lee, M.D
1. Towards treatment for the complex patient: investigations of low-intensity focused ultrasound.
2. Escitalopram for Agitation in Alzheimers Disease (S-CitAD). Closed
3. Low Intensity Focused Ultrasound for Tobacco Use Disorder: Parametric Targeting of the Human Insula, Nucleus Accumbens, and Anterior Cingulate Cortex.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Frank Liu, M.D
1. An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
2. A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Iutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Arti, M.D
1. A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone In Participants with Advanced Nonsmall Cell Lung Cancer Who have Progressed on prior Anti-PD-(L)1 Therapy and Chemotherapy (COSTAR LUNG).
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Chelsie Morrison, M.D
1. Veterans Affairs (VA) Lipid Optimization Reimagined (VALOR-QI) in Veterans with Atherosclerotic Cardiovascular Disease (ASCVD) VA Multisite Project. (Project).
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Seshagiri Nandula, M.D
1. Effect of HIV medications on cardiometabolic health in African American Veterans.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Eric Nylen, M.D Need to change
1. Urinary Proadrenomedullin to improve risk stratification of children with community-acquired pneumonia.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Vasilios Papademetriou, M.D
1. The TARGET BP I Trial: A Pivotal, Multicenter, Blinded, Sham-Procedure-Controlled Trial of Renal Denervation by the Peregrine™ System Kit, in Subjects with Hypertension.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Mercedes Quinones, M.D
1. Vectra InVolved Informed Decision Outcome Study (VIVID): A prospective randomized controlled trial evaluating the effect of guided care with Vectra on compared to treatment as usual in patients with rheumatoid arthritis.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Atoosa Rabiee, M.D
1. Study to test the safety and dose of proglumide as an antifibrotic agent in Non alcoholic steatohepatitis. closed
2. ML44719, A PHASE II, OPEN-LABEL, MULTI-COHORT, MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS.
3. ALTUS: Performance of a Multi-Target Hepatocellular Carcinoma (HCC) Test in Subjects with Increased Risk.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Sabyasachi Sen, M.D
1. Role of Empagliflozin in African American Veterans with Non-Diabetic Chronic Kidney Disease.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Pamela Steele, M.D
1. A Multicenter, Randomized, Double-Blind, Parallel Group, PlaceboControlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Matthew Tuck, M.D
1. A primary role for the circulatory microenvironment in African American prostate cancer disparities.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Qing Zeng, M.D
1. Long-Term Outcomes of Antipsychotic Medication Use in Veterans with PTSD.
2. MVP Data Integration into the ADSP phenotype harmonization consortium.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Mitchell Wallin, M.D
1. Risk Factors for Preclinical MS: The ENGEMS Cohort- Genetic and Environmental Risk Factors for Multiple Sclerosis.
2. Real-World Clinical Trial of an Online Cognitive Behavioral Therapy for Managing Fatigue in MS.
3. National Multiple Sclerosis Society.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Maneesh Jain, M.D
1. Identification of Targetable Prostate Cancer Alterations Through Tumor DNA Screening.
Contact: instituteclinicalresearch@gmail.com
Principal Investigator: Zirong Zhao, M.D
1. Randomized, placebo-controlled cross-over trial evaluating topical lidocaine patches for mechanical neck pain.
Contact: instituteclinicalresearch@gmail.com
Active Studies
Study Status
Principal Investigator
Protocol Title
Sponsor
Open for Enrollment
Maneesh Jain, MD
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fam-Trastuzumab Deruxtecan-Nxki (T-DXd) as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma
Daiichi Sankyo, Inc.
Open for Enrollment
Gail Kerr, MD
Identifying Novel Biomarkers of Disease Progression in Rheumatoid Arthritis-Associated Interstitial Lung Disease
University of Pittsburgh (Foundation award)
Open for Enrollment
Mary Lee, MD
Towards treatment for the complex patient: investigations of low-intensity focused ultrasound.
National Institute of Health
Open for Enrollment
Ping Li, MD
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals, Inc.
Open for Enrollment
Dalia Mobarek, MD
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (the “Study”).
Johnson & Johnson
Open for Enrollment
Atoosa Rabiee, MD
ML44719, A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Genentech
Open for Enrollment
Sabyasachi Sen, MD, PhD
Role of Empagliflozin in African American Veterans with Non-Diabetic Chronic Kidney Disease
Boehringer Ingelheim
Open for Enrollment
Matthew Tuck, MD
A Primary Role for the Circulatory Microenvironment in African American Prostate Cancer Disparities
US Department of Defence
Open for Enrollment
Jose Vargas, MD
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis due to Non-Alcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Akero Therapeutics, Inc.

